| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.5 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.046 | 0.5 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | 0.02 | 0.5 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.5 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.021 | 0.5 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.5 |
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | -0.1 | 0.5 |